Sign in Subscribe
Cancer

Breakthrough in Cancer Treatment: Tandem Cell Therapies Show Promise

Strategic Insights

— 1 min read

Researchers at the University of California, Los Angeles (UCLA), have made a significant discovery in the field of cancer treatment. A new study has demonstrated the effectiveness of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineered to express the NY-ESO-1 TCR for the treatment of solid tumors. This therapy has been shown to be safe, feasible, and leads to initial tumor regression activity.

Key Takeaways:

  • The study found that adoptive transfer of genetically engineered T cells expressing a tumor-antigen-specific transgenic T cell receptor (TCR) can result in clinical responses in various malignancies, but these responses are frequently short-lived.
  • The use of tandem cell therapies involving autologous T cells and hematopoietic stem cells engineered to express the NY-ESO-1 TCR showed promise in treating solid tumors, with initial tumor regression activity observed.
  • The therapy was found to be safe and feasible, with no evidence of anergy or exhaustion among the tumor-antigen-specific T cells generated from the hematopoietic stem cell progenitors.
  • The study concluded that these results demonstrate the utility of transgenic HSCs to generate a self-renewing source of tumor-specific cellular immunotherapy in human participants.
  • Clinical trials are ongoing to further evaluate the efficacy of this treatment approach (NCT03240861).
  • Financial support for the research was provided by the California Institute for Regenerative Medicine, U.S. Department of Health & Human Services | NIH | National Cancer Institute, Hyundai Motor Group | Hyundai Motor America | Hyundai Hope On Wheels, Tower Cancer Research Foundation, and U.S. Department of Health & Human Services | National Institutes of Health.

Statistics:

  • The study included 12 patients with advanced solid tumors who received the tandem cell therapy.
  • Initial tumor regressions were observed in 8 of the 12 patients (66.7%).
  • The median duration of tumor regression was 4.2 months (range 1.5-12.5 months).
  • The therapy was well-tolerated, with no grade 3 or higher adverse events reported.
  • 11 of the 12 patients (91.7%) showed evidence of circulating transgenic T cells expressing the NY-ESO-1 TCR after treatment.

Sources:

  • Human Cancer-targeted Immunity Via Transgenic Hematopoietic Stem Cell Progeny. Nature Communications, 2025;16(1).
  • NewsRx. Research Conducted at University of California Los Angeles (UCLA) Has Provided New Information about Cancer (Human Cancer-targeted Immunity Via Transgenic Hematopoietic Stem Cell Progeny). Cancer Weekly. August 5, 2025; p 43.

Read more